Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**3-fluoro-N‑1H‑indol‑5‑yl‑5‑morpholin‑4‑ylbenzamide** is a synthetic small molecule belonging to the phenylmorpholine class, characterized by an indole and morpholine moiety attached to a fluorinated benzamide core. It has been identified as an inhibitor of mitogen‐activated protein kinase 14 (MAPK14, also known as p38α MAP kinase), though with relatively low potency (IC₅₀ ≈162 μM). There are no approved indications or clinical trials for this compound; it is primarily used in research settings as a chemical probe or fragment for studying MAPK14 inhibition[1][6][4]. No evidence exists of its development by any pharmaceutical company for therapeutic use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide.